JACOBS LEVY EQUITY MANAGEMENT, INC
Position in HALO — Halozyme Therapeutics, Inc.
CIK 884414
FLORHAM PARK, NJ
Position in HALO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$25,232,447
-$25,788,349 QoQ
Shares Held
322,377
-59.2% QoQ
Ownership
0.284%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#74
of 664 holders
Holding Since
Mar 2020
7 quarters on record
Voting authority
Sole 74%
Shared 0%
None 26%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $741,570,791 across 81 Biotechnology names. HALO ranks #5 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
256,503 | $159,939,880 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,939,719 | $98,157,217 | |
| 3 | INCY |
Incyte Corp
|
731,774 | $82,953,900 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
695,532 | $60,476,507 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
This page
|
322,377 | $25,232,447 | |
| 6 | EXEL |
Exelixis, Inc.
|
415,650 | $22,615,516 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,231,516 | $20,898,826 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
60,986 | $18,358,615 |
All Filings in HALO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $25,232,447 | 322,377 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $51,020,796 | 789,429 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $59,019,206 | 876,957 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $65,873,401 | 898,192 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $52,156,240 | 1,002,619 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $11,636,008 | 182,354 | Shares | Sole | 2025-05-15 | |
| 2020-03-31 | $3,575,908 | 198,772 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||